Market revenue in 2023 | USD 192.5 million |
Market revenue in 2030 | USD 320.7 million |
Growth rate | 7.6% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 68.62% in 2023. Horizon Databook has segmented the Brazil blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The Brazilian government has implemented various initiatives to improve cancer care, including national cancer control programs and funding for cancer research & diagnostics. Policies subsidizing diagnostic tests & treatments make these services more affordable and accessible to the general population.
Furthermore, government support for research and innovation in medical diagnostics fosters the development of new & improved diagnostic technologies. These policy measures expand the blood cancer diagnostics market by enhancing the availability and quality of diagnostic services.
In March 2024, Fundação Oswaldo Cruz (Fiocruz), a foundation under Brazil's MoH, partnered with Caring Cross, a nonprofit organization, to establish local manufacturing capabilities for CAR-T cell and stem cell gene therapies in Brazil. These therapies are expected to target oncology, infectious diseases, and genetic disorders, including CAR-T cell treatments for lymphoma, leukemia, & HIV infection.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Brazil blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account